Expert consensus on the management of Pseudomonas aeruginosa lower respiratory tract infections

Title: Expert consensus on the management of Pseudomonas aeruginosa lower respiratory tract infections
Edition: Updated
Classification: Experts consensus
Field: Comprehensive guideline
Countries and regions: China
Guidelines users: Physicians, nurses, infection control personnel, clinical microbiology lab technicians, hospital administrators
Evidence classification method:
Development unit: Chinese Thoracic Society Pulmonary Infection assembly
Registration time: 2021-02-01
Registration number: IPGRP-2021CN028
Purpose of the guideline: Pseudomonas aeruginosa (PA) is one of the most common non-fermentative bacterium in the clinical setting, which is widely distributed in nature and can grow as a normal flora in human skin and contaminated medical devices and even disinfectant solutions.PA is an important conditional pathogen of hospital-acquired infections and the multi-drug resistance (MDR) rate is high. The lower respiratory tract is the most common site of hospital-acquired infections, and if it is caused by MDR-PA, the morbidity and mortality rate is high and the treatment is difficult, so it is particularly important to standardize the diagnosis and treatment of PA lower respiratory tract infections. In recent years, progress has been made in the drug resistance epidemiology, detection technology, treatment options and prevention of PA lower respiratory tract infections, therefore, the Chinese Thoracic Society Pulmonary Infection assembly initiated and organized experts to update the Expert consensus on the management of Pseudomonas aeruginosa lower respiratory tract infections developed in 2014.